Physician profile
Eric Lim
NPI 1427130723
$17,455.29
in general payments reported to CMS, 2019-2025
45 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,453 · 2020: $3,479 · 2021: $3,480 · 2022: $1,732 · 2023: $1,700 · 2024: $1,060 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,305 · Education: $5.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,305.19 |
| Education | $5.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,328.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,752.63 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $2,099.22 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $1,314.21 | 2019-2023 | Shingrix, Arexvy |
| Pfizer INC. | $979.85 | 2019-2025 | |
| Novo Nordisk INC | $857.62 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $541.71 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $415.05 | 2019-2023 | Belsomra, Januvia |
| Amarin Pharma, INC. | $413.28 | 2019-2022 | |
| Lilly USA, LLC | $408.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $394.88 | 2019-2024 | |
| Amgen INC. | $382.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $345.76 | 2019-2023 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $323.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.46 | 2021-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.